{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T13:45:35Z","timestamp":1782654335725,"version":"3.54.5"},"reference-count":44,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autologous haematopoietic stem cell transplantation (AHSCT) is a potential therapeutic strategy for patients with relapsing multiple sclerosis (pwRMS) unresponsive to disease-modifying therapies (DMTs), though its optimal position in the treatment algorithm remains undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe treatment outcomes of 30 AHSCT performed in 29 pwRMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective single-centre real-world study. Patients underwent AHSCT between 2001 and 2025. Median age at disease onset, diagnosis, and AHSCT was 21, 23, and 32 years, respectively. Mean EDSS at AHSCT was 3.1 (range 1.0\u20139.0). Median follow-up was 8 years (range 0.5\u201320.6). Carmustine, etoposide, cytarabine, melphalan (BEAM) + anti-thymocyte globulin (ATG) was the most used high-dose chemotherapy regimen. Brain magnetic resonance imaging was performed at 6 months, 12 months, and then annually after AHSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In patients with at least 6 months of follow-up, no evidence of disease activity-3 (NEDA-3) status was present in 16 out of 27 (59.2%); evidence of disease activity appeared after a median time of 33 months (range 5\u201374). NEDA-3 was maintained in 75% of the BEAM\u2009+\u2009ATG subgroup at the last follow-up. In the whole cohort, the mortality rate was 0%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AHSCT is a highly efficacious option for patients with hyperaggressive onset or highly active disease despite the high efficacy of DMTs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552173261437600","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:17:54Z","timestamp":1782389874000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3624-5715","authenticated-orcid":false,"given":"Simona","family":"Malucchi","sequence":"first","affiliation":[{"name":"Department of Neurology and Regional Multiple Sclerosis Referral Center, University Hospital San Luigi Gonzaga, Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-7642","authenticated-orcid":false,"given":"Marco","family":"De Gobbi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Malentacchi","sequence":"additional","affiliation":[{"name":"Department of Neurology and Regional Multiple Sclerosis Referral Center, University Hospital San Luigi Gonzaga, Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ulisciani","sequence":"additional","affiliation":[{"name":"Subintensive Oncohaematology and Bone Marrow Transplant Center, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Ascenzi","sequence":"additional","affiliation":[{"name":"Subintensive Oncohaematology and Bone Marrow Transplant Center, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7052-1907","authenticated-orcid":false,"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[{"name":"University Hospital San Luigi Gonzaga, Neuroscience Institute Cavalieri Ottolenghi (NICO), Turin, ItalyKoelliker Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5575-7567","authenticated-orcid":false,"given":"Alessia","family":"Di Sapio","sequence":"additional","affiliation":[{"name":"Department of Neurology and Regional Multiple Sclerosis Referral Center, University Hospital San Luigi Gonzaga, Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2023.06.002"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Muraro P Mariottini A Greco R et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder \u2013 recommendations from ECTRIMS and the EBMT. Nat Rev Neurol 2025; 21: 140\u2013158.","DOI":"10.1038\/s41582-024-01050-x"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251349129"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00200-9"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004228"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70130"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494"},{"key":"e_1_3_3_9_2","volume-title":"Proceedings of the ACTRIMS Forum 2025","author":"Leist T","unstructured":"Leist T. Safety of cladribine tablets in the treatment of people with multiple sclerosis: 2024 post-approval update with a focus on infection risk. In Proceedings of the ACTRIMS Forum 2025; 27 February\u20131 March 2025, Poster P400; 2025, West Palm Beach, FL, USA."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004313"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231194823"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001126"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000480"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2224556"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001329"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18743"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1184"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27247"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206750"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1373385"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003660"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319446"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-2933-6"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13147"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012449"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011461"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520914818"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323992"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104829"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14324"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","unstructured":"Mariottini A Nozzoli C Repice A et al. Long-term outcomes of autologous hematopoietic stem cell transplantation in aggressive multiple sclerosis. Ectrims 2024 oral presentation O020\/734.","DOI":"10.3389\/fimmu.2024.1478777"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520985238"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70017-1"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02397-x"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331864"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519893926"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78160-1"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-328797"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104210"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241231665"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105096"},{"key":"e_1_3_3_42_2","first-page":"146","article-title":"Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK","volume":"97","author":"Muraro PA","year":"2025","unstructured":"Muraro PA, Kazmi M, De Matteis E, et al. Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK. J Neurol Neurosurg Psychiatry 2025; 97: 146\u2013155.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07308-y"},{"key":"e_1_3_3_44_2","doi-asserted-by":"crossref","unstructured":"Hughesi SL Prettyjohns MJ Snowden JA et al. Economics of hematopoietic stem cell transplant in immune-mediated neurologic autoimmune diseases. In: Inglese M Mancardi GL (eds) Handbook of Clinical Neurology. (3rd Series) Hematopoietic Stem Cell Transplantation for Neurologic Diseases. Elsevier 2024 Vol. 202 pp.279\u2013294. https:\/\/doi.org\/10.1016\/B978-0-323-90242-7.00007-9.","DOI":"10.1016\/B978-0-323-90242-7.00007-9"},{"key":"e_1_3_3_45_2","unstructured":"NET-MS Study Investigators. No evidence of disease activity after autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis (NET-MS). EudraCT Number: 2022-002654-95. Available at: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2022-002654-95\/IT"}],"container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261437600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173261437600","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261437600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T13:17:44Z","timestamp":1782652664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173261437600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/20552173261437600"],"URL":"https:\/\/doi.org\/10.1177\/20552173261437600","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"value":"2055-2173","type":"print"},{"value":"2055-2173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"20552173261437600"}}